Form S-1

SolarMax Technology, Inc. Announces Pricing of Initial Public Offering and listing on Nasdaq

Retrieved on: 
Tuesday, February 27, 2024
Prospectus, Suite, Sale, Form, Form S-1, Solar Maximum Mission

The initial public offering is comprised of 4,500,000 shares of common stock, priced at a public offering price of $4.00 per share.

Key Points: 
  • The initial public offering is comprised of 4,500,000 shares of common stock, priced at a public offering price of $4.00 per share.
  • In addition, SolarMax has granted the underwriters a 45-day option to purchase an additional 675,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions, to cover over-allotments.
  • The shares are expected to begin trading on the Nasdaq Global Market on February 27, 2024 under the ticker symbol "SMXT."
  • The closing of the public offering is expected to take place on or about February 29, 2024, subject to the satisfaction or waiver of customary closing conditions.

Banzai is Pleased to Announce Effectiveness of its Form S-1 Registration Statement

Retrieved on: 
Thursday, February 15, 2024
Investment, Form, Form S-1, Security (finance)

SEATTLE, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Banzai International, Inc. (NASDAQ: BNZI) (“Banzai” or the “Company”), a leading marketing technology company that provides essential marketing and sales solutions, today announced that the Securities and Exchange Commission ("SEC") has declared the Company's registration statement on Form S-1 (Registration No.

Key Points: 
  • SEATTLE, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Banzai International, Inc. (NASDAQ: BNZI) (“Banzai” or the “Company”), a leading marketing technology company that provides essential marketing and sales solutions, today announced that the Securities and Exchange Commission ("SEC") has declared the Company's registration statement on Form S-1 (Registration No.
  • 333-276307) effective as of 5:00 PM ET on February 14, 2024.
  • The effectiveness of the S-1 brings Banzai one step closer to accessing capital under the Yorkville Advisors Standby Equity Purchase Agreement (SEPA), which provides the Company the option to sell to Yorkville up to $100 million of Banzai’s shares of Class A common stock.
  • Commented Banzai’s Founder and CEO, Joe Davy, “Financing under the SEPA, once available, will support Banzai’s ability to execute on our planned acquisitions and make other critical investments supporting our 2024 Profitable Growth strategy.”

Vivos Therapeutics Announces Exercise of Warrants for Approximately $4.0 Million Aggregate Gross Proceeds

Retrieved on: 
Thursday, February 15, 2024
OSA, Sleep, Obstructive sleep apnea, Sale, Exercise, Form, Form S-1, Therapy, Security (finance)

As part of this transaction, the investor agreed to exercise the existing warrant (which was originally issued in November 2023 and had an exercise price of $3.83 per share) at a revised exercise price of $4.02 per share.

Key Points: 
  • As part of this transaction, the investor agreed to exercise the existing warrant (which was originally issued in November 2023 and had an exercise price of $3.83 per share) at a revised exercise price of $4.02 per share.
  • The resale of the shares of common stock issuable upon exercise of the warrant were registered pursuant to an effective registration statement on Form S-1 (No.
  • Such warrants are identical, except that one warrant has a term of five years and the second warrant has a term of eighteen months.
  • Vivos intends to use the net proceeds from the exercise for general corporate purposes.

Evoke Pharma Announces Closing of $7.5 Million Public Offering

Retrieved on: 
Wednesday, February 14, 2024
Attention, Suite, Telephone, Evoke, Fifth Avenue, Sale, Equity capital markets, Form, Series, Capital Group Companies, Form S-1, Security (finance), Metoclopramide, Prescription

"We are pleased to have closed this offering with these fundamental, healthcare-oriented institutional investors," stated Evoke Pharma Chief Executive Officer Dave Gonyer.

Key Points: 
  • "We are pleased to have closed this offering with these fundamental, healthcare-oriented institutional investors," stated Evoke Pharma Chief Executive Officer Dave Gonyer.
  • If the Series A Warrants are exercised in full, the Company would receive an additional $7.5 million in gross proceeds.
  • If the Series B Warrants are exercised in full, the Company would receive an additional $7.5 million in gross proceeds.
  • Evoke intends to use the net proceeds from the public offering for working capital and general corporate purposes.

Azitra, Inc. Announces Pricing of Public Offering

Retrieved on: 
Wednesday, February 14, 2024
Biotechnology, Pharmaceutical, Health, Other Health, ThinkEquity, Prospectus, Sale, Form, State Street, Form S-1, Security (finance), Research

Azitra, Inc. (NYSE American: AZTR) (“Company”), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the pricing of an underwritten public offering of 16,667,000 shares of common stock.

Key Points: 
  • Azitra, Inc. (NYSE American: AZTR) (“Company”), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the pricing of an underwritten public offering of 16,667,000 shares of common stock.
  • Each share of common stock is being sold at a public offering price of $0.30 per share for gross proceeds of approximately $5 million, before deducting underwriting discounts and offering expenses.
  • In addition, Azitra has granted the underwriters a 45-day option to purchase up to an additional 2,500,000 shares of common stock to cover over-allotments at the public offering price, less the underwriting discount.
  • The offering is expected to close on February 16, 2024, subject to satisfaction of customary closing conditions.

Revelation Biosciences Inc. Announces Closing of $6.2 Million Public Offering

Retrieved on: 
Monday, February 5, 2024
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Roth Capital Partners, Immunity, Colorectal surgery, Trial of the century, Form S-1, AKI, Prospectus, Revelation, Disease, Infection, Sale, Suite, Form, Security (finance)

The warrants have an exercise price of $4.53 per share, are exercisable upon issuance, and will expire five years following the date of issuance.

Key Points: 
  • The warrants have an exercise price of $4.53 per share, are exercisable upon issuance, and will expire five years following the date of issuance.
  • Roth Capital Partners acted as sole placement agent for the offering.
  • The gross proceeds to the Company from the offering are approximately $6.2 million, before deducting the placement agent’s fees and other offering expenses payable by Revelation.
  • 333-276232), as amended, that was declared effective by the U.S. Securities and Exchange Commission (“SEC”), on January 31, 2024.

GRI Bio Announces Pricing of $5.5 Million Public Offering

Retrieved on: 
Friday, February 2, 2024
Security (finance), GRI, Offering, Form S-1, Madison Avenue, Telephone, Prospectus, Sale, Series, Natural killer T cell, Form

The closing of the Offering is expected to occur on or about February 6, 2024, subject to the satisfaction of customary closing conditions.

Key Points: 
  • The closing of the Offering is expected to occur on or about February 6, 2024, subject to the satisfaction of customary closing conditions.
  • The gross proceeds from the Offering are expected to be approximately $5.5 million.
  • The Company intends to use the net proceeds from the Offering for working capital and other general corporate purposes.
  • The Offering is being made only by means of a prospectus forming part of the effective registration statement.

Bullfrog AI Announces Pricing of $5.7 Million Public Offering

Retrieved on: 
Thursday, February 1, 2024
Security (finance), Bullfrog, Form S-1, Machine learning, Prospectus, Artificial intelligence, Sale, Form

The Company intends to use the net proceeds from the offering for working capital and other general corporate purposes.

Key Points: 
  • The Company intends to use the net proceeds from the offering for working capital and other general corporate purposes.
  • The offering is expected to close on February 5, 2024, subject to satisfaction of customary closing conditions.
  • WallachBeth Capital, LLC is acting as sole book-running manager for the offering.
  • In addition, a copy of the final prospectus, when available, relating to the offering may be obtained via the SEC's website at www.sec.gov .

Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option

Retrieved on: 
Wednesday, January 31, 2024
EDGAR, SAN, Indian stock exchange, Form S-1, Warrant, Telephone, Public, Exercise, Prospectus, TSX, ATTN:, Private placement, Public offering, Suite, Private, Toronto Stock Exchange, Form, Security (finance)

Aptose also announced the closing of the previously announced US $4 million private placement (the “Private Placement”) of Common Shares with Hanmi Pharmaceutical, Inc. (“Hanmi”), Seoul, South Korea, yielding ownership of 19.03% of the outstanding Common Shares of the Company.

Key Points: 
  • Aptose also announced the closing of the previously announced US $4 million private placement (the “Private Placement”) of Common Shares with Hanmi Pharmaceutical, Inc. (“Hanmi”), Seoul, South Korea, yielding ownership of 19.03% of the outstanding Common Shares of the Company.
  • Total gross proceeds from the public offering and private placement were approximately $13.7 million, excluding underwriting discounts, placement agent commissions and other offering-related expenses.
  • The total number of Common Shares outstanding after the closing of the Public Offering, including the Over-Allotment Option, and Private Placement is 15,706,810 and warrants outstanding are 8,332,163.
  • Newbridge Securities Corporation acted as the sole book-running manager for the Public Offering and as placement agent for the Private Placement.

60 Degrees Pharmaceuticals Announces Closing of $2.4 Million Public Offering

Retrieved on: 
Wednesday, January 31, 2024
Form, Security (finance), Degree, Research, Form S-1, Warrant, Unit, Prospectus, Sale, Suite, Infection, Malaria

WASHINGTON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals , Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharmaceuticals” or the “Company”), specialists in developing and marketing new medicines for the treatment and prevention of infectious diseases, announced today the closing of its public offering of 5,260,901 units (the “Units”) at a price to the public of $0.385 per Unit and 999,076 pre-funded units (the “Pre-Funded Units”) at a price to the public of $0.375 per Pre-Funded Unit.

Key Points: 
  • WASHINGTON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals , Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharmaceuticals” or the “Company”), specialists in developing and marketing new medicines for the treatment and prevention of infectious diseases, announced today the closing of its public offering of 5,260,901 units (the “Units”) at a price to the public of $0.385 per Unit and 999,076 pre-funded units (the “Pre-Funded Units”) at a price to the public of $0.375 per Pre-Funded Unit.
  • Each Unit consists of one share of common stock and one warrant exercisable for one share of common stock (the “Warrant”).
  • The Pre-Funded Warrants are immediately exercisable and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full.
  • The gross proceeds to the Company from the offering were approximately $2.4 million, before deducting underwriter fees and other offering expenses payable by the Company.